多西环素联合阿奇霉素治疗儿童大环内酯无反应性肺炎支原体肺炎的临床观察OA

Objective To investigate the clinical efficacy and safety of doxycycline combined with azithromycin in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia(MUMPP)in children.Methods A total of 100 children with MUMPP treated at the hospital from August 2023 to December 2024 were enrolled and randomly divided into two groups using a random number table,with 50 patients in each group.The control group continued azithromycin monotherapy,whereas the observation group received doxycycline in addition to azithromycin.Clinical efficacy,time to resolution of symptoms including wheezing,cough,pulmonary rales,and fever,pulmonary function parameters,inflammatory indicators,and adverse reactions were compared between the two treatment groups.Results The clinical response rate was higher in the observation group than in the control group.The times to resolution of wheezing,pulmonary rales,high fever,and cough were shorter in the observation group.Forced expiratory volume in 1 second(FEV1),forced vital capacity(FVC),peak expiratory flow(PEF),and FEV1/FVC were higher,whereas white blood cell count(WBC)and high-sensitivity C-reactive protein(hs-CRP)levels were lower,in the observation group than in the control group,with statistically significant differences(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Compared with continued azithromycin monotherapy,doxycycline combined with azithromycin can improve the therapeutic efficacy of MUMPP in children,accelerate symptom resolution,reduce inflammatory responses,and promote recovery of pulmonary function.